In a major step aimed at strengthening patient safety and promoting rational use of medicines, the Central Government has prohibited the manufacture, sale, and distribution of 16 fixed-dose combination (FDC) drugs across the country, citing safety concerns and lack of therapeutic justification.
The decision, taken by the Ministry of Health and Family Welfare, comes after a detailed scientific review which concluded that the potential risks associated with these combinations outweigh their benefits. The government said that only scientifically validated and effective medicines should be available in the market to ensure public health safety.
Registration Begins for FutureCrime Summit 2026, India’s Largest Cybercrime Conference
Fixed-dose combination drugs are formulations that contain two or more active pharmaceutical ingredients in a fixed ratio. These combinations are often used to simplify treatment regimens, but require strong scientific validation to ensure safety and effectiveness.
According to the ministry, the review was conducted in compliance with directions of the Supreme Court. Following this, the Drugs Technical Advisory Board (DTAB) constituted an expert committee to examine several drug combinations and identify those that were irrational, unsafe, or therapeutically unjustified.
The government order stated that the manufacture, sale, distribution, and supply of the identified 16 FDCs for human use stand prohibited with immediate effect across India. Officials said the decision was taken after it was found that these combinations lacked therapeutic justification and were not beneficial when compared to their potential risks.
The banned formulations reportedly include combinations used in dermatological treatments, pain management, antispasmodic therapies, and antibiotic-based medicines. Several of these combinations were found unsuitable following expert evaluation.
The ministry further noted that similar actions have been taken in the past against irrational FDCs after scientific assessments. The latest move is part of a broader policy to promote rational drug use and enhance patient safety standards in the country.
State drug controllers, regulatory authorities, and enforcement agencies have been instructed to ensure strict implementation of the ban. Manufacturers, importers, and distributors have also been directed to take immediate corrective measures to comply with the order.
An expert committee review found that several combinations lacked clear scientific rationale, and their continued use could expose patients to unnecessary health risks. Based on these findings, the DTAB recommended regulatory action leading to the ban.
The government emphasized that the decision is part of ongoing efforts to improve drug quality and eliminate irrational formulations from the healthcare system. Officials said such measures ensure that only safe and evidence-based medicines remain in circulation.
The pharmaceutical industry is expected to be impacted, as several companies were reportedly producing these combinations. Experts believe the move will further strengthen regulatory compliance and push manufacturers toward more scientifically validated formulations.
Health experts noted that while fixed-dose combinations can improve patient compliance, poorly designed combinations may complicate treatment and increase risks. Regulatory intervention, they said, is essential in such cases to safeguard public health.
The order has been issued under Section 26A of the Drugs and Cosmetics Act, 1940, which empowers the central government to prohibit the manufacture and sale of any drug in public interest. This provision has been used earlier to remove unsafe or irrational drugs from the market.
Officials added that continued scientific reviews are expected in the future to ensure that no unsafe or unapproved formulations remain in circulation.
The move is being seen as a significant step toward strengthening India’s drug regulatory framework and ensuring that the healthcare system prioritizes safety, efficacy, and scientific validity in medicines available to the public.
